[ TRANSACTION RECORD ]

Biogen Inc. Investment in Reata Pharmaceuticals — 2023

VERIFIED VECTOR ID: 001902 · tx-098-2
M SOURCE NODE — FUNDER
Biogen Inc.
Healthcare United States
$7,300,000,000
EQUITY
26/09/2023
Q DESTINATION NODE — RECIPIENT
Reata Pharmaceuticals
Company United States
Amount (USD)
$7.3B
Flow Type
EQUITY
Transaction Date
26/09/2023
Primary Source
View Filing ↗
Funder Profile [ M ]
Entity Biogen Inc.
AUM 32000
HQ Location United States
Sector Healthcare
Recipient Profile [ Q ]
Entity Reata Pharmaceuticals
Entity Type Company
Jurisdiction United States
Intelligence Note

Biogen Inc. finalized the 7.3 billion dollar acquisition of Reata Pharmaceuticals to strengthen its presence in rare neurological disease treatments. The transaction includes the recently approved drug Skyclarys for Friedreich’s ataxia. This deal represents a major institutional investment in the high-growth orphan drug market within the healthcare sector.

Σ
Primary Forensic Source https://investors.biogen.com/news-releases/news-release-details/biogen-completes-acquisition-reata-pharmaceuticals-inc/
✓ SOURCE LINKED